Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Diane Orlinsky

Dermatology Towson, MD Medical Doctor

NPI 1194771642 CMS profile 189952

8320 Bellona Ave, Suite 20, Towson, MD 21204

Open in the dashboard

General payments

$7,542

321 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Diane Orlinsky of Towson, MD is reported in the CMS Open Payments database as having received $7,542 across 321 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $921 35
2024 General $940 39
2023 General $1,069 44
2022 General $1,031 51
2021 General $1,407 48
2020 General $916 45
2019 General $1,258 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Diane Orlinsky
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Diane Orlinsky were reported at $921. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Diane Orlinsky Dermatology median Middle half National median
2019 $1,258 $454 $129–$1,240 $163
2020 $916 $235 $81–$756 $114
2021 $1,407 $377 $108–$1,108 $132
2022 $1,031 $514 $143–$1,391 $149
2023 $1,069 $607 $159–$1,674 $160
2024 $940 $751 $204–$1,903 $164
2025 $921 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $746 24 payments
  2. Novartis Pharmaceuticals Corporation $728 40 payments
  3. Galderma Laboratories, L.P. $650 39 payments
  4. Pfizer Inc. $605 28 payments
  5. Allergan Inc. $554 10 payments
  6. Sun Pharmaceutical Industries Inc. $473 24 payments
  7. Molecular Biologicals, Inc $403 2 payments
  8. Almirall LLC $369 19 payments
  9. Genzyme Corporation $367 14 payments
  10. Janssen Biotech, Inc. $332 11 payments
  11. Other $2,314 110 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,036 310 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $437 10 payments
  3. Education $69 1 payment
Products named General payments · program years 2019–2025
  1. EUCRISA $534 24 payments
  2. Winlevi $421 20 payments
  3. Keragel $403 2 payments
  4. COSENTYX $368 24 payments
  5. BOTOX COSMETIC $367 7 payments
  6. DUPIXENT $319 12 payments
  7. RINVOQ $287 13 payments
  8. CIBINQO $254 12 payments
  9. SOTYKTU $234 13 payments
  10. OPZELURA $225 11 payments
  11. Other $4,612 215 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

214

Median for Dermatology: 534

Drug cost

$4,478

Median for Dermatology: $67,151

Branded share of claims

5.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluorouracil Generic 24 $1,413
Ciclopirox Generic 22 $812
Ciclopirox Ciclopirox Olamine Brand 11 $566
Gentamicin Sulfate Generic 11 $419
Mupirocin Generic 59 $371
Clobetasol Propionate Generic 12 $257
Triamcinolone Acetonide Generic 23 $226
Doxycycline Hyclate Generic 13 $176
Minoxidil Generic 22 $161
Hydrocortisone Generic 17 $80

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Winlevi
  • Sun Pharmaceutical Industries Inc. $128
$128 — —
TREMFYA
  • Janssen Biotech, Inc. $85
$85 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $66
$66 — —
TALTZ
  • Lilly USA, LLC $51
$51 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

321 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record